Carboplatin and docetaxel in patients with salivary gland carcinoma: A retrospective study

Takuro Okada; Takashi Saotome; Toshitaka Nagao; Tatsuo Masubuchi; Chihiro Fushimi; Takashi Matsuki; Hideaki Takahashi; Kouki Miura; Kiyoaki Tsukahara; Yuichiro Tada

doi:10.21873/invivo.11549

Carboplatin and docetaxel in patients with salivary gland carcinoma: A retrospective study

Takuro Okada, Takashi Saotome, Toshitaka Nagao, Tatsuo Masubuchi, Chihiro Fushimi, Takashi Matsuki, Hideaki Takahashi, Kouki Miura, Kiyoaki Tsukahara, Yuichiro Tada

Head & Neck Surgery

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Background/Aim: The aim of this study was to evaluate the efficacy and safety of carboplatin/docetaxel combination therapy in patients with locally advanced and/or recurrent/metastatic (LA/RM) salivary gland carcinoma (SGC). Materials and Methods: This was a retrospective analysis of 24 patients that included six patients with AR-positive salivary duct carcinoma (SDC) after progressive disease treated with combined androgen blockade (CAB). Carboplatin (AUC5) and docetaxel (70 mg/m²) were administered for six courses every three weeks. Results: The overall response rate was 42%, the median progression-free survival was 8.4 months, and the median overall survival was 26.4 months. Among the six patients with CAB-resistant SDC, two achieved a partial response and two long-term stable disease. Grade 3/4 neutropenia and anemia were observed in 20-30% of the patients; all adverse events were manageable. Conclusion: Carboplatin/docetaxel combination therapy may be a chemotherapeutic option for patients with LA/RM SGC, and a valuable second-line chemotherapy for CAB-resistant, AR-positive SDC.

Original language	English (US)
Pages (from-to)	843-853
Number of pages	11
Journal	In Vivo
Volume	33
Issue number	3
DOIs	https://doi.org/10.21873/invivo.11549
State	Published - May 2019

Keywords

Androgen receptor
Carboplatin
Docetaxel
Human epithelial growth factor receptor 2
Salivary duct carcinoma
Salivary gland carcinoma

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
Pharmacology

Access to Document

10.21873/invivo.11549

Cite this

@article{82cfa6cf294441d697fc14b3778ebc1b,

title = "Carboplatin and docetaxel in patients with salivary gland carcinoma: A retrospective study",

abstract = "Background/Aim: The aim of this study was to evaluate the efficacy and safety of carboplatin/docetaxel combination therapy in patients with locally advanced and/or recurrent/metastatic (LA/RM) salivary gland carcinoma (SGC). Materials and Methods: This was a retrospective analysis of 24 patients that included six patients with AR-positive salivary duct carcinoma (SDC) after progressive disease treated with combined androgen blockade (CAB). Carboplatin (AUC5) and docetaxel (70 mg/m2) were administered for six courses every three weeks. Results: The overall response rate was 42%, the median progression-free survival was 8.4 months, and the median overall survival was 26.4 months. Among the six patients with CAB-resistant SDC, two achieved a partial response and two long-term stable disease. Grade 3/4 neutropenia and anemia were observed in 20-30% of the patients; all adverse events were manageable. Conclusion: Carboplatin/docetaxel combination therapy may be a chemotherapeutic option for patients with LA/RM SGC, and a valuable second-line chemotherapy for CAB-resistant, AR-positive SDC.",

keywords = "Androgen receptor, Carboplatin, Docetaxel, Human epithelial growth factor receptor 2, Salivary duct carcinoma, Salivary gland carcinoma",

author = "Takuro Okada and Takashi Saotome and Toshitaka Nagao and Tatsuo Masubuchi and Chihiro Fushimi and Takashi Matsuki and Hideaki Takahashi and Kouki Miura and Kiyoaki Tsukahara and Yuichiro Tada",

note = "Funding Information: This work was supported by JSPS Grants-in-Aid for Scientific Research (C) to Dr. Yuichiro Tada (No. 18K09386) and Dr. Toshitaka Nagao (No. 17K08705). The authors thank Editage (www.editage.jp) for English language editing. Publisher Copyright: {\textcopyright} 2019 International Institute of Anticancer Research. All rights reserved.",

year = "2019",

month = may,

doi = "10.21873/invivo.11549",

language = "English (US)",

volume = "33",

pages = "843--853",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "3",

}

TY - JOUR

T1 - Carboplatin and docetaxel in patients with salivary gland carcinoma

T2 - A retrospective study

AU - Okada, Takuro

AU - Saotome, Takashi

AU - Nagao, Toshitaka

AU - Masubuchi, Tatsuo

AU - Fushimi, Chihiro

AU - Matsuki, Takashi

AU - Takahashi, Hideaki

AU - Miura, Kouki

AU - Tsukahara, Kiyoaki

AU - Tada, Yuichiro

N1 - Funding Information: This work was supported by JSPS Grants-in-Aid for Scientific Research (C) to Dr. Yuichiro Tada (No. 18K09386) and Dr. Toshitaka Nagao (No. 17K08705). The authors thank Editage (www.editage.jp) for English language editing. Publisher Copyright: © 2019 International Institute of Anticancer Research. All rights reserved.

PY - 2019/5

Y1 - 2019/5

N2 - Background/Aim: The aim of this study was to evaluate the efficacy and safety of carboplatin/docetaxel combination therapy in patients with locally advanced and/or recurrent/metastatic (LA/RM) salivary gland carcinoma (SGC). Materials and Methods: This was a retrospective analysis of 24 patients that included six patients with AR-positive salivary duct carcinoma (SDC) after progressive disease treated with combined androgen blockade (CAB). Carboplatin (AUC5) and docetaxel (70 mg/m2) were administered for six courses every three weeks. Results: The overall response rate was 42%, the median progression-free survival was 8.4 months, and the median overall survival was 26.4 months. Among the six patients with CAB-resistant SDC, two achieved a partial response and two long-term stable disease. Grade 3/4 neutropenia and anemia were observed in 20-30% of the patients; all adverse events were manageable. Conclusion: Carboplatin/docetaxel combination therapy may be a chemotherapeutic option for patients with LA/RM SGC, and a valuable second-line chemotherapy for CAB-resistant, AR-positive SDC.

AB - Background/Aim: The aim of this study was to evaluate the efficacy and safety of carboplatin/docetaxel combination therapy in patients with locally advanced and/or recurrent/metastatic (LA/RM) salivary gland carcinoma (SGC). Materials and Methods: This was a retrospective analysis of 24 patients that included six patients with AR-positive salivary duct carcinoma (SDC) after progressive disease treated with combined androgen blockade (CAB). Carboplatin (AUC5) and docetaxel (70 mg/m2) were administered for six courses every three weeks. Results: The overall response rate was 42%, the median progression-free survival was 8.4 months, and the median overall survival was 26.4 months. Among the six patients with CAB-resistant SDC, two achieved a partial response and two long-term stable disease. Grade 3/4 neutropenia and anemia were observed in 20-30% of the patients; all adverse events were manageable. Conclusion: Carboplatin/docetaxel combination therapy may be a chemotherapeutic option for patients with LA/RM SGC, and a valuable second-line chemotherapy for CAB-resistant, AR-positive SDC.

KW - Androgen receptor

KW - Carboplatin

KW - Docetaxel

KW - Human epithelial growth factor receptor 2

KW - Salivary duct carcinoma

KW - Salivary gland carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85065333191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065333191&partnerID=8YFLogxK

U2 - 10.21873/invivo.11549

DO - 10.21873/invivo.11549

M3 - Article

C2 - 31028207

AN - SCOPUS:85065333191

SN - 0258-851X

VL - 33

SP - 843

EP - 853

JO - In Vivo

JF - In Vivo

IS - 3

ER -

Carboplatin and docetaxel in patients with salivary gland carcinoma: A retrospective study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this